ADEMPAS DIN 02412772
Health Canada record
| Active ingredient(s) | RIOCIGUAT 1 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C02KX05 RIOCIGUAT |
| Original market date | 25-Sep-2013 |
| Current status date | 25-Sep-2013 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RIOCIGUAT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02412764 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 0.5 MG | Marketed |
| 02412799 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 1.5 MG | Marketed |
| 02412802 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 2 MG | Marketed |
| 02412810 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 2.5 MG | Marketed |
| 02533545 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 0.5 MG | Marketed |
| 02533561 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 1 MG | Marketed |
| 02533588 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 1.5 MG | Marketed |
| 02533596 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 2 MG | Marketed |
| 02533618 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 2.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14748 | 2013-09-19 | New Drug Submission (NDS) |
International API supply for RIOCIGUAT
1 valid EDQM Certificates of Suitability from 1 holders. 7 active FDA Drug Master Files.
Request a quote for ADEMPAS